Studie - Pneumonia – Pipeline Review, H1 2012

Pneumonia — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Pneumonia - Pipeline Review, H1 2012', provides an overview of the Pneumonia therapeutic pipeline. This report provides information on the therapeutic development for Pneumonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pneumonia. 'Pneumonia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- A snapshot of the global therapeutic scenario for Pneumonia.
- A review of the Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pneumonia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Pneumonia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pneumonia pipeline depth and focus of Pneumonia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Pneumonia Overview 8

Therapeutics Development 9

An Overview of Pipeline Products for Pneumonia 9

Pneumonia Therapeutics under Development by Companies 11

Pneumonia Therapeutics under Investigation by Universities/Institutes 15

Late Stage Products 17

Comparative Analysis 17

Mid Clinical Stage Products 18

Comparative Analysis 18

Early Clinical Stage Products 19

Comparative Analysis 19

Discovery and Pre-Clinical Stage Products 20

Comparative Analysis 20

Pneumonia Therapeutics — Products under Development by Companies 21

Pneumonia Therapeutics — Products under Investigation by Universities/Institutes 23

Companies Involved in Pneumonia Therapeutics Development 24

Johnson & Johnson 24

Sequella, Inc. 25

AstraZeneca PLC 26

GlaxoSmithKline plc 27

Nektar Therapeutics 28

Takeda Pharmaceutical Company Limited 29

Nanotherapeutics, Inc. 30

Rib-X Pharmaceuticals, Inc. 31

Optimer Pharmaceuticals, Inc. 32

Bayer AG 33

Intercell AG 34

Basilea Pharmaceutica Ltd. 35

Oragenics, Inc. 36

Pacgen Biopharmaceuticals Corporation 37

Advanced Life Sciences Holdings, Inc. 38

Lipoxen PLC 39

Dongwha Pharm Co., Ltd. 40

Synairgen plc 41

Eurocine Vaccines AB 42

Mucosis B.V. 43

Aridis Pharmaceuticals LLC 44

Kenta Biotech Ltd. 45

aRigen Pharmaceuticals, Inc. 46

Nabriva Therapeutics AG 47

Enanta Pharmaceuticals, Inc. 48

KaloBios Pharmaceuticals, Inc. 49

Trius Therapeutics, Inc. 50

Tetraphase Pharmaceuticals Inc. 51

TaiGen Biotechnology Co., Ltd. 52

Endacea, Inc. 53

APEPTICO Forschung und Entwicklung GmbH 54

Pneumonia — Therapeutics Assessment 55

Assessment by Monotherapy Products 55

Assessment by Combination Products 56

Assessment by Route of Administration 57

Assessment by Molecule Type 59

Drug Profiles 62

BAY41-6551 - Drug Profile 62

MEDI-534 - Drug Profile 64

NKTR-063 - Drug Profile 65

Restanza - Drug Profile 66

Restanza - Drug Profile 68

Teflaro - Drug Profile 70

Teflaro - Drug Profile 72

NanoGENT - Drug Profile 74

MU1140 - Drug Profile 75

BC-3205 - Drug Profile 76

KBPA101 - Drug Profile 77

RX-3341 - Drug Profile 78

RX-1741 - Drug Profile 81

PAC-525 - Drug Profile 83

PAC-G31P - Drug Profile 84

KB001 - Drug Profile 85

SQ641 - Drug Profile 87

LipoNeu - Drug Profile 88

L-97-1 - Drug Profile 89

OP-1068 - Drug Profile 91

Tedizolid Phosphate - Drug Profile 93

DW-224 - Drug Profile 94

EDP-420 - Drug Profile 96

IC43 - Drug Profile 97

Pneumococcal Vaccines - Drug Profile 98

Nemonoxacin - Drug Profile 99

Aerucin - Drug Profile 101

PneuGEM - Drug Profile 102

Moxifloxacin - Drug Profile 103

Enbrel - Drug Profile 104

Amoxicillin - Drug Profile 105

Trimetrexate Glucuronate + Leucovorin Calcium - Drug Profile 106

Chloramphenicol - Drug Profile 107

Chlorhexidine - Drug Profile 109

Prevnar - Drug Profile 110

Interferon Beta Programme - Drug Profile 111

Cotrimoxazole - Drug Profile 113

Enbrel + Corticosteroids - Drug Profile 114

Urokinase - Drug Profile 116

Prednisone - Drug Profile 117

Ulinastatin - Drug Profile 118

GSK2189242A - Drug Profile 119

Doribax - Drug Profile 121

Pravastatin - Drug Profile 123

JNJ-Q2 - Drug Profile 124

Nasal Pneumococcal Vaccine - Drug Profile 126

Ceftobiprole Medocaril - Drug Profile 127

Prevnar + Pneumovax 23 - Drug Profile 129

Prevnar + Pneumovax 23 - Drug Profile 130

Pentamidine Isethionate - Drug Profile 131

Pentamidine Isethionate - Drug Profile 132

Panaecin - Drug Profile 133

Hydrocortisone + Fludrocortisone - Drug Profile 134

Oseltamivir - Drug Profile 135

Simvastatin - Drug Profile 136

Zinc - Drug Profile 137

Dapsone - Drug Profile 138

Meropenem - Drug Profile 139

Synflorix + Infanrix Hexa - Drug Profile 140

GSK1024850A + Tritanrix-HepB/Hib + Polio Sabin - Drug Profile 141

Human Parainfluenza Type 3 Virus Vaccine - Drug Profile 143

Meiact MS Fine Granules - Drug Profile 145

Colistin - Drug Profile 146

AP301 - Drug Profile 147

TP-834 - Drug Profile 149

Trivalent Inactivated Influenza Vaccine - Drug Profile 150

Methylprednisolone - Drug Profile 152

Whole Cell Pertussis Vaccine + Pneumococcal Surface Protein A (PspA)Antigen - Drug Profile 153

TP-271 - Drug Profile 154

Pneumonia Therapeutics — Drug Profile Updates 155

Pneumonia Therapeutics — Discontinued Products 167

Pneumonia Therapeutics - Dormant Products 168

Pneumonia — Product Development Milestones 170

Featured News & Press Releases 170

Appendix 177

Methodology 177

Coverage 177

Secondary Research 177

Primary Research 177

Expert Panel Validation 178

Contact Us 178

Disclaimer 178





List of Tables

Number of Products Under Development for Pneumonia, H1 2012 14

Products under Development for Pneumonia — Comparative Analysis, H1 2012 15

Number of Products under Development by Companies, H1 2012 17

Number of Products under Development by Companies, H1 2012 (Contd..1) 18

Number of Products under Development by Companies, H1 2012 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H1 2012 21

Comparative Analysis by Late Stage Development, H1 2012 22

Comparative Analysis by Mid Clinical Stage Development, H1 2012 23

Comparative Analysis by Early Clinical Stage Development, H1 2012 24

Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 25

Products under Development by Companies, H1 2012 26

Products under Investigation by Universities/Institutes, H1 2012 28

Johnson & Johnson, H1 2012 29

Sequella, Inc., H1 2012 30

AstraZeneca PLC, H1 2012 31

GlaxoSmithKline plc, H1 2012 32

Nektar Therapeutics, H1 2012 33

Takeda Pharmaceutical Company Limited, H1 2012 34

Nanotherapeutics, Inc., H1 2012 35

Rib-X Pharmaceuticals, Inc., H1 2012 36

Optimer Pharmaceuticals, Inc., H1 2012 37

Bayer AG, H1 2012 38

Intercell AG, H1 2012 39

Basilea Pharmaceutica Ltd., H1 2012 40

Oragenics, Inc., H1 2012 41

Pacgen Biopharmaceuticals Corporation, H1 2012 42

Advanced Life Sciences Holdings, Inc., H1 2012 43

Lipoxen PLC, H1 2012 44

Dongwha Pharm Co., Ltd., H1 2012 45

Synairgen plc, H1 2012 46

Eurocine Vaccines AB, H1 2012 47

Mucosis B.V., H1 2012 48

Aridis Pharmaceuticals LLC, H1 2012 49

Kenta Biotech Ltd., H1 2012 50

aRigen Pharmaceuticals, Inc., H1 2012 51

Nabriva Therapeutics AG, H1 2012 52

Enanta Pharmaceuticals, Inc., H1 2012 53

KaloBios Pharmaceuticals, Inc., H1 2012 54

Trius Therapeutics, Inc., H1 2012 55

Tetraphase Pharmaceuticals Inc., H1 2012 56

TaiGen Biotechnology Co., Ltd., H1 2012 57

Endacea, Inc., H1 2012 58

APEPTICO Forschung und Entwicklung GmbH, H1 2012 59

Assessment by Monotherapy Products, H1 2012 60

Assessment by Combination Products, H1 2012 61

Assessment by Stage and Route of Administration, H1 2012 63

Assessment by Stage and Molecule Type, H1 2012 66

Pneumonia Therapeutics — Drug Profile Updates 160

Pneumonia Therapeutics — Discontinued Products 172

Pneumonia Therapeutics — Dormant Products 173





List of Figures

Number of Products under Development for Pneumonia, H1 2012 14

Products under Development for Pneumonia — Comparative Analysis, H1 2012 15

Products under Development by Companies, H1 2012 16

Products under Investigation by Universities/Institutes, H1 2012 20

Late Stage Products, H1 2012 22

Mid Clinical Stage Products, H1 2012 23

Early Clinical Stage Products, H1 2012 24

Discovery and Pre-Clinical Stage Products, H1 2012 25

Assessment by Monotherapy Products, H1 2012 60

Assessment by Combination Products, H1 2012 61

Assessment by Route of Administration, H1 2012 62

Assessment by Stage and Route of Administration, H1 2012 63

Assessment by Molecule Type, H1 2012 64

Assessment by Stage and Molecule Type, H1 2012 65

• Bronchopulmonary Dysplasia – Pipeline Review, H1 2013
• Bronchospasm Global Clinical Trials Review, H1, 2013
• Cystic Fibrosis – Pipeline Review, H1 2013
• Diphtheria – Pipeline Review, H1 2013
• EpiCast Report: Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2022
• OpportunityAnalyzer: Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017
• OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2017
• Acute Respiratory Distress Syndrome – Pipeline Review, H1 2013
• Asthma – Pipeline Review, H1 2013
• Bronchiectasis – Pipeline Review, H1 2013
• Candidiasis – Pipeline Review, H1 2013
• EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2022
• Lung Disease – Pipeline Review, H1 2013
• Nasal Congestion Global Clinical Trials Review, H1, 2013
• Perennial Allergic Rhinitis – Pipeline Review, H1 2013
• Respiratory Tract Inflammatory Disorders – Pipeline Review, H1 2013
• Allergic Rhinitis – Pipeline Review, H1 2013
• Bronchiectasis Global Clinical Trials Review, H1, 2013
• Chronic Bronchitis – Pipeline Review, H1 2013
• EpiCast Report: Pediatric Respiratory Syncytial Virus Infection and Prophylactic Populations in the US - Epidemiology Forecast to 2022